Ovid Therapeutics Stock Price, News & Analysis (NASDAQ:OVID)

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.08. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Ovid Therapeutics.

6 Wall Street analysts have issued 1 year price objectives for Ovid Therapeutics' stock. Their predictions range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' share price to reach $14.80 in the next twelve months. This suggests a possible upside of 560.7% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

News coverage about OVID stock has been trending somewhat negative on Saturday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 426,400 shares, an increase of 10.8% from the July 31st total of 384,800 shares. Based on an average trading volume of 288,800 shares, the short-interest ratio is presently 1.5 days. Currently, 2.3% of the company's stock are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Prothena (PRTA), MediciNova (MNOV), OptiNose (OPTN), Minerva Neurosciences (NERV), Theratechnologies (THERF), Avid Bioservices (CDMO), Ardelyx (ARDX), Forty Seven (FTSV), Albireo Pharma (ALBO), Atreca (BCEL), BIOFRONTERA AG/ADR (BFRA), Kindred Biosciences (KIN), Urovant Sciences (UROV), OvaScience (OVAS) and CV Sciences (CVSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Marinus Pharmaceuticals (MRNS), Verastem (VSTM), Anavex Life Sciences (AVXL), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.84%), Cowen Inc. (2.51%), Cowen Inc. (2.51%), Renaissance Technologies LLC (1.22%), Wells Fargo & Company MN (1.14%) and Acadian Asset Management LLC (0.55%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Cowen Inc., Cowen Inc., Morgan Stanley, Charles Schwab Investment Management Inc., JPMorgan Chase & Co. and Northern Trust Corp. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, Paloma Partners Management Co, Acadian Asset Management LLC and Jane Street Group LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $2.24.

Ovid Therapeutics has a market capitalization of $86.67 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]